Prevention of Thrombotic Disorders in Cancer Patients Undergoing Chemotherapy

• References

• 1 Rickies FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31
• 2 Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metast Rev 1992; 11: 237-248
• 3 Rogers JS, Murgo AJ, Fontana VA, Raich PC. Chemotherapy for breast cnacer decreases plasma protein C and protein S. J Clin Oncol 1988; 06: 276-281
• 4 Edwards RL, Klaus M, Mathews E. et al Heparin abolishes the chemotherapy induced increase in plasma fibriopeptide A levels. Am J Med 1990; 89: 25-28
• 5 Bertomeu MC, Gallo S, Lauri D. et al Chemotherapy enhances endothelial reactivity to platelets. Clin Exp Metast 1990; 08: 511-518
• 6 Levine MN, Gent M, Hirsh J. et al The thrombogenic effect of anticancer drug therapy in women with Stage II breast cancer. N Eng J Med 1988; 318: 404-407
• 7 Weiss RB, Tormey DC, Holland JF. et al Venous thrombosis during multimodal treatment of primary breast cancer. Cancer Treat Rep 1981; 65: 677-679
• 8 Goodnough LT, Saito H, Manni A. et al Increased incidence of thromboembolism in stage IV breast caner patients treated with a five-day chemotherapy regimen. A study of 159 patients. Cancer 1984; 54: 1264-1268
• 9 Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant chemotherapy for breast cancer. J Clin Oncol 1991; 09: 286-294
• 10 Pritchard KI, Paterson AHG, Paul NA. et al Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996; 14: 2731-2737
• 11 Wall JG, Weiss RB, Norton L. et al Arterial thrombosis associated with adjuvant chemotherapy for breast cancer: a Cancer and Leukemia Group B study. Am J Med 1989; 87: 501-504
• 12 Tempelhoff GF, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996; 14: 2560-2568
• 13 Clahsen PC, van de VeldeCJH, Julien JP. et al Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Breast Cancer Cooperative Group Study. J Clin Oncol 1994; 12: 1266-1271
• 14 Fisher B, Redmond C, Legault Poisson. et al Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumours responsive to tamoxifen: results from the national surgical adjuvant breast and bowel project B16. J Clin Oncol 1990; 08: 1005-1018
• 15 Rifkin SE, Green S, Metch B. et al Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal node positive and estrogen receptor positive breast cancer patients: a Southwest Oncology Group Study. J Clin Oncol 1994; 12: 2078-2085
• 16 Fisher B, Constantino J, Redmond C. et al A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumours. N Eng J Med 1989; 320: 479-484
• 17 Barbui T, Finazzi G, Grassi A, Marchioli R. Thrombosis in cancer patients treated with hematolopoietic growth factors — a meta-analysis. Thrombos Haemost 1996; 75: 368-371
• 18 Levine M, Hirsh J, Gent M. et al Double blind randomised trial of very-low-dose warfarin for the prevention of thromboembolism in Stage IV breast cancer. Lancet 1994; 343: 886-889
• 19 Rajan R, Gafni A, Levine M, Hirsh J, and Gent M. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol 1995; 13: 42-46
• 20 Bern MM, Lokich JJ, Wallach SR. et al Very low doses of warfarin can prevent thrombosis in central vein catheters: a randomized prospective trial. Ann Intern Med 1990; 112: 4232-4428
• 21 Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep vein thrombosis in cancer patients with venous access devices — prophylaxis with a low molecular weight heparin (fragmin). Thrombos Haemost 1996; 75: 251-253
• 22 Levine MN, Hirsh J, Gent M. et al Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-611